Stimulant Psychosis: What Meth Detox Really Involves

Methamphetamine withdrawal gets waved off as safe more often than almost any other kind. The reasoning sounds sensible: meth withdrawal doesn’t produce the seizures or the delirium that make alcohol and benzodiazepine withdrawal immediately life-threatening, so people conclude there’s nothing much to watch. That comparison is right on one narrow point and wrong about everything that matters. The danger in meth detox isn’t a seizure. It’s psychiatric.

Stimulant psychosis can begin while someone is still using, and it can carry straight through withdrawal and past the point where the drug has cleared the body. Underneath it sits a crash phase that brings heavy depression and a real risk of suicide. Those two things, taken together, are why methamphetamine detox belongs in a setting where clinicians are watching around the clock, whatever the seizure risk happens to be.

Key Takeaways

• Meth withdrawal lacks the seizure risk of alcohol or benzodiazepines, but it carries a serious psychiatric risk that makes supervision necessary.
• Psychosis is common among people who use methamphetamine, and it can persist after the drug has left the body.
• The crash phase brings deep depression and craving, and methamphetamine is a strong independent predictor of suicidality.
• No medication is approved for stimulant use disorder the way methadone and buprenorphine are approved for opioid use disorder.
• Contingency management has the strongest research support of any treatment for stimulant use disorder.

What Stimulant Psychosis Actually Is

Stimulant psychosis is a break from shared reality brought on by heavy stimulant use. It usually shows up as some combination of paranoia, hallucinations, and delusions, and clinicians see a fairly consistent pattern. StatPearls describes amphetamine-related psychosis as involving persecutory delusions and visual hallucinations that closely resemble the acute psychosis seen in schizophrenia.

What surprises people most is that it doesn’t require active intoxication. The National Institute on Drug Abuse notes that methamphetamine can produce hallucinations and delusions even when a person is not currently high. Someone can be days into abstinence and still hear voices or be convinced they’re being followed.

It’s also far from rare. A meta-analysis of 17 studies published in Psychiatry Research found a composite prevalence of 36.5% for methamphetamine-induced psychotic disorder, rising to 42.7% when researchers looked at lifetime occurrence and 43.3% among people who met criteria for a methamphetamine use disorder. Roughly four in 10 people who use meth heavily will experience this at some point.

Common features include:

• Persecutory beliefs, often a conviction of being watched, followed, or targeted
• Visual hallucinations, which are more typical here than in many primary psychotic illnesses
• Auditory hallucinations and tactile sensations on or under the skin
• Disorganized thinking and rapid shifts in mood
• Intense fear, because the experience is genuinely terrifying from the inside

Worth saying plainly: a person in this state is unwell, not bad. The beliefs feel completely real to them, and the fear that comes with them is real fear. This is a medical condition that responds to treatment, and it deserves to be treated like one.

How Stimulant Psychosis Differs From a Primary Psychotic Illness

Telling the two apart during an acute episode is genuinely hard. StatPearls acknowledges that it’s difficult for a clinician to distinguish amphetamine-associated psychosis from the acute psychosis of a primary mental disorder, because in the moment they can look nearly identical.

The clearest difference is often the trajectory. Substance-induced psychosis usually improves faster once the substance is gone, with many people recovering substantially within about a week of abstinence. A primary psychotic illness follows its own course and doesn’t clear simply because someone stops using.

That distinction has a long tail, though. Research summarized by StatPearls indicates that roughly 30% of people with amphetamine-induced psychosis eventually go on to develop a primary psychotic disorder. So a stimulant-induced episode isn’t always a closed chapter, and it can be an early signal of something that needs its own long-term treatment.

This is why good detox programs hold off on a firm psychiatric diagnosis in the first days. Clinicians are weighing several things at once:

• Whether symptoms track with recent use or continue independently of it
• Whether the person has any psychiatric history predating stimulant use
• Family history of psychotic illness
• How symptoms respond over the first week or two of abstinence
• Whether other substances or medical problems are contributing

Sorting that out properly takes time and observation, which is part of what treating addiction and mental health together is designed to provide.

Why Psychosis Can Outlast the Drug

Methamphetamine clears the body in a matter of days. The psychosis doesn’t reliably follow that schedule. Most episodes settle within weeks, but a meaningful share run considerably longer, and StatPearls points to Japanese research showing that recovery from amphetamine-induced psychosis can stretch out over a much longer period, in some cases years.

There’s a second wrinkle. Once someone has experienced stimulant psychosis, the brain seems to stay primed for it. NIDA reports that heavy drinking and stress raise the odds that a person who has had methamphetamine-associated psychosis before will have psychotic symptoms again. A later episode can arrive with less provocation than the first.

That lingering vulnerability is one reason the withdrawal period needs clinical eyes on it, not just a quiet room and good intentions. It’s a different mechanism from psychosis brought on by alcohol, which is tied more closely to the withdrawal state itself, but both point in the same direction: substance-induced psychosis is a reason for medical care, not a reason to wait and see.

What Methamphetamine Withdrawal Really Looks Like

Research has mapped the withdrawal course, and it splits into recognizable phases rather than one undifferentiated bad week.

The Crash

A study in Addiction tracking people through their first three weeks of abstinence found that withdrawal severity peaks within 24 hours of last use and then declines steadily. The crash is dominated by heavy sleeping, a sharp return of appetite, and a cluster of depression symptoms, with anxiety and craving present but less severe. People often describe it as being flattened rather than being in pain.

The Acute Phase

That same research put the acute phase at roughly seven to 10 days, with symptom severity dropping in a fairly linear pattern from its early peak toward normal levels. NIDA describes acute withdrawal as peaking two to three days after last use and lasting about a week, bringing depression, anxiety, irritability, pain, sleep problems, cravings, and trouble concentrating.

Extended Anhedonia and Cravings

The part people are least prepared for comes after the acute phase ends. Addiction researchers found a subacute phase lasting at least another two weeks, and NIDA notes that low mood, anxiety, and cravings can continue for several months.

The defining feature of this stretch is anhedonia, the inability to feel pleasure from anything. Food, music, people, and work all go flat. Someone can be physically fine and still describe life as gray and pointless. Anyone who has read about what the first week of cocaine detox feels like will recognize the shape of it, since stimulants share this pattern, though the meth version tends to run longer.

Why the Psychiatric Risk Is the Reason for Supervised Care

Put the crash and the psychosis side by side, and the argument for supervision makes itself. StatPearls states that methamphetamine is a strong independent predictor of suicidality, and recommends that psychiatric assessment be performed during the withdrawal phase specifically to evaluate for suicidal thinking and other psychiatric complications.

That risk peaks precisely when a person is least equipped to manage it: deep in a depressive crash, possibly still experiencing paranoia or hallucinations, exhausted, and often isolated. The connection between substance use and suicidal thinking is well documented, and stimulant withdrawal concentrates several of the risk factors at once.

If you or someone you know is having thoughts of suicide, call or text 988 to reach the 988 Suicide and Crisis Lifeline, which is free, confidential, and available 24 hours a day.

This is also why the absence of seizure risk is the wrong thing to plan around. Nobody should be attempting to get through meth withdrawal alone on the theory that it’s survivable. The question isn’t whether the body can technically endure it. It’s whether anyone is present to notice psychosis taking hold or suicidal thinking setting in, and to act on it. The difference between medical detox and trying to quit without support comes down to exactly that kind of monitoring.

What Monitoring and Stabilization Involve

Supervised stimulant detox is less about administering a specific antidote and more about steady observation with a team that can intervene quickly. A typical course includes:

1. A full intake covering substance use history, psychiatric history, and current symptoms
2. Medical assessment and lab work, since stimulant use strains the heart and can mask other problems
3. Structured psychiatric evaluation repeated through the withdrawal period rather than done once
4. A low-stimulation environment, which matters a great deal when someone is paranoid or overwhelmed
5. Medication targeted at specific symptoms such as agitation, sleeplessness, or persistent psychotic symptoms, chosen and adjusted by a physician
6. Attention to sleep, hydration, and nutrition, all of which are usually badly depleted
7. Repeated suicide risk assessment, especially as the crash deepens
8. Planning for continuing care before discharge

One clinical point is worth highlighting: StatPearls advises that clinicians should never delay treatment of a suspected amphetamine-related psychiatric problem while waiting on toxicology results. Care starts on presentation, not on lab confirmation.

Why There’s No Approved Medication for Stimulant Use Disorder

Opioid use disorder has approved medications with decades of evidence behind them, including methadone and buprenorphine. Stimulant use disorder has nothing equivalent. NIDA states directly that there’s no FDA-approved medication for methamphetamine use disorder or any other stimulant use disorder, and SAMHSA’s treatment protocol for stimulant use disorders says the same.

The reason is partly biological—opioid medications work by acting on a single well-characterized receptor system. Stimulants act broadly across dopamine, norepinephrine, and serotonin systems, and researchers haven’t found a compound that corrects the imbalance without creating new problems. Research continues, and a 2026 paper in Addiction argued that the evidence gap in managing stimulant-induced psychosis needs urgent attention, but nothing is approved today.

Medications still get used during detox, prescribed for particular symptoms rather than for the underlying disorder. The practical consequence is that the behavioral and supportive side of treatment carries the weight here in a way it doesn’t with opioids.

Contingency Management and the Behavioral Core of Treatment

The strongest evidence in this field sits behind contingency management. SAMHSA’s guidance is unusually direct about it, describing contingency management as by far the psychosocial treatment with the greatest scientific support for stimulant use disorders.

The approach is simple in structure. A person receives a tangible, immediate reward each time a drug test confirms abstinence, with the reward escalating for sustained stretches. It works because it replaces a reliable, near-term reward the brain has lost during anhedonia, when nothing feels rewarding. The case for staying abstinent is hardest to feel.

It’s normally combined with other approaches that also have support behind them:

• Cognitive behavioral therapy, for managing triggers and thought patterns
• Community reinforcement, which builds rewarding activities and relationships back into daily life
• Motivational interviewing, for strengthening a person’s own reasons to continue
• Group support and peer connection
• Psychiatric follow-up, particularly when psychotic symptoms persist past detox

Because the extended phase runs long, what happens after the acute days matters as much as detox itself. Someone whose anhedonia is still lifting at week six needs structure. Detox stabilizes the acute crisis; the months afterward are where recovery is actually built.

References

• Amphetamine-Related Psychiatric Disorders – StatPearls, NCBI Bookshelf
• Methamphetamine – National Institute on Drug Abuse
• The Prevalence of Substance-Induced Psychotic Disorder in Methamphetamine Misusers: A Meta-Analysis – Psychiatry Research
• The Nature, Time Course and Severity of Methamphetamine Withdrawal – Addiction
• Methamphetamine – StatPearls, NCBI Bookshelf
• Treatment for Stimulant Use Disorders – Substance Abuse and Mental Health Services Administration